IGF-1 LR3 vs Sermorelin

Long-acting analog of IGF-1 that binds to IGF-1 receptors, promoting muscle protein synthesis, cellular growth, and recovery. Suppresses myostatin activity and has a significantly extended half-life compared to native IGF-1 due to reduced binding protein affinity.

IGF-1-LR3 (Long Arg3 IGF-1) is a synthetic 83-amino-acid analog of insulin-like growth factor 1, engineered with an N-terminal 13-amino-acid extension and an Arg3 substitution that substantially reduces binding to IGF-binding proteins (IGFBPs), resulting in a biological half-life approximately 120 times longer than native IGF-1 and theoretically greater receptor availability in peripheral tissues. The reduced IGFBP affinity means a higher proportion of circulating IGF-1-LR3 remains unbound and potentially bioactive; in vitro cell proliferation studies and animal models suggest amplified anabolic signaling relative to equimolar native IGF-1, and the compound is widely used as a research reagent in cell culture for controlled IGF-1R stimulation without the confounding effects of endogenous binding protein dynamics. No human pharmacokinetic, safety, or efficacy studies of IGF-1-LR3 have been published in PubMed-indexed journals; the indexed scientific literature consists of in vitro proliferation studies, animal metabolic research, and anti-doping detection methods — a complete absence of clinical data supporting or characterizing its use in humans. IGF-1-LR3 has no FDA approval or regulatory approval in any jurisdiction; it is a research laboratory reagent and non-approved analog available through research chemical suppliers, and the complete absence of published human data means its pharmacological behavior, tissue distribution, and safety profile in humans are entirely uncharacterized. IGF-1 LR3 in research contexts: as a laboratory reagent, IGF-1-LR3 is used at nanomolar concentrations in cell culture assays to stimulate IGF-1 receptor signaling. The extended half-life (approximately 20–30 hours compared to native IGF-1's 15 minutes) is the primary reason for its use in research settings requiring sustained IGF-1R activation. In animal pharmacology studies, doses vary widely by species and model; these cannot be directly extrapolated to human dosing, and no safe or effective human dose has been established. Its extended half-life relative to native IGF-1 is also the property most frequently cited in anti-doping detection literature, where the compound has been identified in biological samples from competitive athletes. The absence of any human clinical data distinguishes IGF-1-LR3 from growth hormone secretagogues such as sermorelin, ipamorelin, or MK-677, which have documented human pharmacological profiles. Providers offering researched GH-axis peptides with clinical datasets are listed in the PeptideBase directory.

Sermorelin is a synthetic analogue of the first 29 amino acids of endogenous growth hormone-releasing hormone (GHRH). It binds to GHRH receptors on pituitary somatotrophs, stimulating pulsatile GH secretion in a physiological pattern that preserves the natural hypothalamic-pituitary feedback axis — contrasting with direct GH administration. Downstream IGF-1 elevation mediates many of its body composition, tissue-repair, and sleep quality effects.

Sermorelin acetate is a synthetic 29-amino-acid peptide (GHRH(1-29)NH2) corresponding to the biologically active N-terminal fragment of endogenous growth hormone-releasing hormone, developed as a prescription pharmaceutical to stimulate endogenous GH secretion from the pituitary gland as a diagnostic and therapeutic agent for GH deficiency. Sermorelin acts on pituitary somatotrophs via GHRH receptors to stimulate pulsatile GH release, preserving the natural feedback regulation of the GH axis — an advantage over direct exogenous GH administration — and multiple randomized controlled trials have established its pharmacokinetic and pharmacodynamic profile in populations with GH insufficiency including post-irradiation hypopituitarism. The compound received FDA approval as Geref (Serono) for diagnosis and treatment of GH deficiency in children; approval was voluntarily withdrawn by the manufacturer in 2008 for commercial rather than safety reasons, leaving the underlying human evidence base intact, and compounded sermorelin has since been widely used off-label in adult anti-aging and hormone optimization practice. Sermorelin is currently available only through compounding pharmacies under prescriber supervision; it is not FDA-approved for any current indication, and its use in adults represents off-label prescribing outside the regulatory framework established by its original pediatric approval. Sermorelin is available through telehealth platforms and hormone optimization clinics across the United States and is dispensed by compounding pharmacies under licensed prescriber supervision. Patients searching for sermorelin providers near them or via telehealth can use the PeptideBase directory to browse verified clinics and telehealth platforms offering sermorelin by location. Sermorelin bodybuilding and anti-aging research contexts have driven its widespread compounded use in adults, though these applications are off-label and outside the original pediatric approval framework. Sermorelin near me: sermorelin is available through licensed anti-aging clinics, hormone health practices, and telehealth platforms that specialize in growth hormone axis support. Because sermorelin requires a prescription, access involves a clinical consultation — many providers now offer this remotely via telehealth, eliminating the need for in-person visits. For those searching for sermorelin providers near them, PeptideBase maintains a directory of verified clinics and telehealth platforms offering sermorelin protocols across the United States. Sermorelin and ipamorelin together: yes, sermorelin and ipamorelin are frequently combined in clinical research and compounded hormone optimization protocols. The two peptides act on different receptors — sermorelin on GHRH receptors (stimulating the GHRH pathway) and ipamorelin on ghrelin receptors (GHS-R1a) — and their mechanisms are complementary rather than redundant. Combining a GHRH analog like sermorelin with a GHRP like ipamorelin produces synergistic GH release, consistent with the well-established pharmacological principle that GHRH and GH secretagogues act additively at the pituitary. Ipamorelin is specifically valued in this combination for its selectivity — it stimulates GH without the cortisol or prolactin co-stimulation that characterizes less selective GHRPs such as GHRP-2 or GHRP-6. The sermorelin + ipamorelin combination (and its extension, the sermorelin + CJC-1295 + ipamorelin triple protocol) is among the most commonly prescribed compounded GH secretagogue regimens in anti-aging and hormone optimization practice. Providers offering combination GH secretagogue protocols are listed in the PeptideBase directory.